Troy Warren host of LetsTalkBusinessRadio.Com revealed his findings today regarding the science and patent pending ingredients that are within the new Momentis product line called M-Rejuvenate.

Part of Warren’s curiosity is his belonging to the Baby Boomer generation that is the biggest generation America has ever known and according to AARP will affect the aging industry immensely over the next 18 years as more than 10,000 people turn 65 each and every day.

In 2014 Momentis International acquired the science, patents and intellectual property behind this clinically approved anti-aging product.

Momentis hired Dr. Dwain Morris-Irvin as its Chief Science Officer and is recognized as one of the top stem cell scientists in the world.  

Dr. Morris-Irvin leads all basic science and clinical research projects. He received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery. 

Dr. Morris-Irvin received his PhD in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells. He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson’s disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells. Dr. Morris-Irvin also worked as a Research Scientist, Assistant Professor, and Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery. He led research investigations in the role of adaptive immunity in Parkinson’s disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). He research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized these data to develop novel immunotherapies for brain tumor patients.

Momentis is led by CEO Andy McWilliams, President Mike Adams and Executive VP of Sales & Field Development Muzafer Najfi.  All inquiries should be directed to 5085 West Park Blvd., Ste 200, Plano, TX 75093 – Phone 1(469) 270-5533

###

Contact LTBR:

Troy Warren
480-720-5478
troy@letstalkbusinessradio.com